Low-Dose Nedaplatin (CDGP:Cis-Diammine-Glycolatoplatinum)/5-FU Combined With Radiation for Esophageal Cancer
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
The purpose of this study is to clarify efficacy and toxicity of daily low-dose Nedaplatin (CDGP) and continuous infusion of 5-FU combined with radiation in patients with esophageal squamous cell carcinoma.
Condition | Intervention | Phase |
---|---|---|
Esophageal Cancer Squamous Cell Carcinoma |
Drug: CDGP/5-FU combined with radiation Radiation: Radiotherapy |
Phase 2 |
Study Type: | Interventional |
Study Design: | Allocation: Non-Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Single Group Assignment Masking: Open Label Primary Purpose: Treatment |
Official Title: | A Phase II Study of Daily Low-Dose of Nedaplatin (CDGP:Cis-Diammine-Glycolatoplatinum) and Continuous Infusion of 5-FU Combined With Radiation for the Treatment of Esophageal Cancer |
- Response rate [ Time Frame: 3 months ] [ Designated as safety issue: No ]
- Adverse events [ Time Frame: every 3-6 months ] [ Designated as safety issue: Yes ]
- Survival rate [ Time Frame: every 3-6 months ] [ Designated as safety issue: No ]
Enrollment: | 33 |
Study Start Date: | January 2003 |
Study Completion Date: | December 2008 |
Primary Completion Date: | September 2008 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
Experimental: 1
Chemoradiotherapy
|
Drug: CDGP/5-FU combined with radiation
Low-dose of Nedaplatin (CDGP) 10 mg/body/day was daily administered on day 1-5, 8-13, 15-19, 22-26 and 5-FU 500 mg/body/day was continuously administered on day 1-5, 8-13, 15-19, 22-26.
Other Names:
Radiation: Radiotherapy
Fractionated external radiotherapy was performed from the first day of chemotherapy and a total dose of 50.4-66 Gy was delivered at the rate of 1.8-2.0 Gy per fraction.
Other Name: Radiation
|
Detailed Description:
The tumor stages and disease grades were classified according to the TNM classification (sixth edition) of the International Union against Cancer (UICC). These were determined conventionally by computed tomography (CT) of the neck, chest and abdomen, bone scan, endoscopic ultrasonography (EUS), endoscopy and esophagography.
Low-dose of Nedaplatin (CDGP) 10 mg/body/day was daily administered on day 1-5, 8-13, 15-19, 22-26 and 5-FU 500 mg/body/day was continuously administered on day 1-5, 8-13, 15-19, 22-26. Fractionated radiotherapy was performed from day 1 and a total dose of 50-60 Gy was delivered at the rate of 1.8-2.0 Gy per fraction. Serotonin receptor antagonist was preventively given as an antinauseant just before the administration of Nedaplatin.
Tumor response was assessed according to the Response Evaluation Criteria In Solid Tumors (UICC, 2002). Toxicities were graded according to the Common Terminology Criteria for Adverse Events v3.0 (CTCAE). Survival was calculated from the start of chemoradiotherapy.
Ages Eligible for Study: | 20 Years to 85 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- newly diagnosed cases histologically as squamous cell carcinoma,
- a performance status 0 to 2,
- white blood cells >3,000/microL,
- platelets >100,000/microL,
- serum total bilirubin <2.0 mg/dl,
- serum transaminase <3 times the upper normal limit,
- serum creatinine <1.5 mg/dl,
- creatinine clearance >60 ml/min
Exclusion Criteria:
- serious cardiac disease
- prior chemotherapy and radiotherapy
Japan | |
First Department of Medicine, Hamamatsu University School of Medicine | |
Hamamatsu, Japan, 431-3192 |
Principal Investigator: | Satoshi Osawa, M.D. | First Department of Medicine, Hamamatsu University School of Medicine |
No publications provided by Hamamatsu University
Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: | Satoshi Osawa, M.D./Ph.D., First Department of Medicine, Hamamatsu University School of Medicine |
ClinicalTrials.gov Identifier: | NCT00197444 History of Changes |
Other Study ID Numbers: | HAMA-M1-C001 |
Study First Received: | September 13, 2005 |
Last Updated: | February 19, 2009 |
Health Authority: | Japan: Ministry of Health, Labor and Welfare |
Keywords provided by Hamamatsu University:
esophageal cancer Nedaplatin 5-FU |
chemotherapy radiation chemoradiotherapy |
Additional relevant MeSH terms:
Carcinoma Carcinoma, Squamous Cell Esophageal Diseases Esophageal Neoplasms Neoplasms, Glandular and Epithelial Neoplasms by Histologic Type Neoplasms Neoplasms, Squamous Cell Gastrointestinal Diseases Digestive System Diseases Gastrointestinal Neoplasms Digestive System Neoplasms Neoplasms by Site |
Head and Neck Neoplasms Fluorouracil Nedaplatin Antimetabolites Molecular Mechanisms of Pharmacological Action Pharmacologic Actions Antimetabolites, Antineoplastic Antineoplastic Agents Therapeutic Uses Immunosuppressive Agents Immunologic Factors Physiological Effects of Drugs |
ClinicalTrials.gov processed this record on October 16, 2012